⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9252238 | 0.98 | SMN1; SMN2 (0.61) | — | |
| SCHEMBL181648 | 0.98 | SMN1; SMN2 (0.61) | — | |
| SCHEMBL181630 | 0.92 | — | — | |
| Arcaine SCHEMBL303546 | 0.87 | MEN1 (0.62) | — | |
| SCHEMBL10728151 | 0.84 | SMN1; SMN2 (0.67) | — | |
| SCHEMBL3072659 | 0.84 | SMN1; SMN2 (0.67) | — | |
| SCHEMBL11882788 | 0.84 | SMN1; SMN2 (0.67) | — | |
| SCHEMBL1923256 | 0.84 | SMN1; SMN2 (0.67) | — | |
| Arcaine SCHEMBL11414566 | 0.84 | MEN1 (0.60) | — | |
| SCHEMBL3069140 | 0.84 | SMN1; SMN2 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2019-09-24 | — | — | US | claimed |
| US-9969773-B2 | Polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2018-05-15 | — | — | US | claimed |
| US-20170015991-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | NEW YORK UNIVERSITY | 2017-01-19 | — | — | US | claimed |
| US-9315548-B2 | Peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2016-04-19 | — | — | US | claimed |
| US-20150011465-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY | 2015-01-08 | — | — | US | claimed |
| US-8828413-B2 | Peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2014-09-09 | — | — | US | claimed |
| US-20130210706-A1 | DENDRIMERIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2013-08-15 | — | — | US | claimed |
| WO-2012026988-A2 | DENDRIMERIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY (US) | 2012-03-01 | — | — | WO | claimed |
| EP-2401264-A2 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | New York University (US) | 2012-01-04 | — | — | EP | claimed |
| WO-2011156003-A2 | PEPTOID AND SYNTHETIC OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2011-12-15 | — | — | WO | claimed |
| EP-1572892-A4 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1751175-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT | Valorisation-Recherche, Société en Commandite (CA) | 2007-02-14 | — | — | EP | claimed |
| US-20060094663-A1 | Interleukin-1 receptor antagonists, compositions, and methods of treatment | VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) | 2006-05-04 | — | — | US | claimed |
| EP-1615653-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2005105830-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT | VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) | 2005-11-10 | — | — | WO | claimed |
| EP-1572892-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | claimed |
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-16 | — | — | US | claimed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | claimed |